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Abstract
Background: Cardiac resynchronization therapy (CRT) improves left ventricular (LV) volumes,
mitral regurgitation (MR) severity and symptoms of patients with heart failure (HF). However, ≥
30% of patients have no significant clinical or echocardiographic improvement following CRT.
Reverse remodeling after CRT correlates with improved clinical outcomes. We hypothesized that
in NT-pro BNP monitoring is accurate to identify responders following CRT.
Methods: 42 consecutive patients (mean age 66 ± 12 years, male 68%) with HF undergoing CRT
were prospectively enrolled. Responders at follow-up were defined by echocardiography (decrease
in LV end systolic volume ≥ 15%). Echocardiography and NT-pro BNP measurement were
performed at baseline and repeated 3 to 6 month after CRT.
Results:  There was no significant difference between responders (n = 29, 69%) and non-
responders (n = 13, 31%) regarding baseline NT-pro BNP level. Responders had significantly higher
decrease in NT-pro BNP levels during follow-up than non-responders (absolute: -1428 ± 1333
pg.ml-1 vs. -61 ± 959 pg.ml-1, p = 0.002; relative: -45 ± 28% vs. 2 ± 28%, p < 0.0001). A decrease of
≥ 15% in NT-pro BNP 3–6 months after CRT identifies echocardiographic responders with a
sensitivity of 90% and a specificity of 77%.
Conclusion: NT-pro BNP monitoring can accurately identify echocardiographic responders after
CRT.
Background
Cardiac resynchronization therapy (CRT) is established as
a valuable additive treatment for patients with drug-
refractory heart failure (HF) and electromechanical asyn-
chrony. CRT improves left ventricular (LV) function and
geometry, exercise capacity and outcomes of appropri-
ately selected patients with HF [1-4]. CRT also leads to a
decrease in both resting and exercise mitral regurgitation
severity [5,6] by enhancement of LV function and local
synchronicity (i.e. mechanical activation of papillary
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muscle insertion sites) [7]. Remodeling is a predictor of
cardiovascular mortality in patients with congestive HF
[1,2]. Reverse remodeling through pharmacological inter-
vention and CRT correlates with improved clinical out-
comes [6]. An important issue in CRT is the problem of
non-responders. Using clinical criteria, rate of non
response to CRT are estimated to be 20–30%, but in stud-
ies using objective parameters of LV remodeling, CRT
non-responder rate reaches 40–50% [8]. Brain natriuretic
peptides (BNP) and its inactive aminoterminal portion
(NT-pro BNP), are neurohormones released by the ventri-
cle in response to increase LV wall stress. Hence, BNP level
may have valuable role for the assessment of cardiac dys-
function, particularly LV dysfunction, and for the moni-
toring of the response to cardiac therapy [9,10]. Recently,
Fruhwald et al[11] showed that CRT leads to an early and
sustained decrease in NT-pro BNP potentially reflecting
improvement in LV function. In responders, left lateral
wall pacing increases systolic function, reduces mitral
regurgitation (MR) and thus decrease the wall motion
stress. In this favorable remodeling process, neurohu-
moral activity is reduced and the decrease in plasma B-
type natriuretic peptide after initiation of CRT predicts
clinical improvement during follow-up [12]. We hypoth-
esized that NT-pro BNP reduction following CRT corre-
lates with LV remodeling and MR improvement and that
change in NT-pro BNP following CRT can identify
echocardiographic responders with good accuracy.
Methods
From May 2005 to March 2008, 42 consecutive patients
referred for CRT with chronic HF were prospectively
enrolled. Inclusion criteria were as follow: (1) NYHA
functional class ≥ III, (2) QRS duration ≥ 120 ms, (3)
chronic LV systolic dysfunction defined as LV ejection
fraction (LVEF) ≤ 35%, (4) LV dyssynchrony ≥ 50 ms, (5)
optimal medical treatment for HF including angiotensin-
converting enzyme inhibitors or AT1 receptor antagonists
diuretics, beta-receptor blockers and spironolactone when
tolerated, and (6) sinus rhythm. Patients with recent myo-
cardial infarction (< 6 months), coronary revasculariza-
tion procedure (< 6 months) and presenting standard
contraindications to DSE were excluded. This study com-
plies with the "Declaration of Helsinki" and all patients pro-
vided informed consent. The study protocol was approved
by local ethics committee.
Protocol
Patients were submitted to clinical examination, 12-lead
electrocardiography (EKG), blood sampling, transtho-
racic echocardiography (TTE), and dobutamine stress
echocardiography (DSE) within one week before CRT.
Additionally, TTE and blood sampling were also per-
formed within the week and at 3 to 6 month following
CRT.
Doppler echocardiography and DSE
Two-dimensional and Doppler TTE examination were
performed with commercially available echocardio-
graphic systems (Sonos 5500 or 7500, Philips Medical
Systems, Amsterdam, The Netherlands). Doppler-
echocardiographic measurements included LV end-
diastolic and end-systolic diameters and LVEF determined
by modified biplane Simpson method. LV outflow tract
stroke volume was calculated by multiplying LV outflow
tract area by LV outflow tract velocity-time integral meas-
ured by pulsed wave Doppler. Proximal isovelocity sur-
face area (PISA) method was used to quantify both mitral
regurgitation volume (RV) and effective regurgitant orifice
(ERO) area as recommended by The American Society of
Echocardiography guideline [13]. Quantification of inter-
ventricular asynchronism was obtained by recording aor-
tic and pulmonary Doppler flows with pulsed wave, from
the apical four-chamber and parasternal short-axis views
respectively. Aortic and pulmonary ejection delays were
defined as the delay between the onset of the QRS com-
plex on the surface EKG and the onset of the aortic and
pulmonary waves. Intraventricular asynchronism meas-
urement was assessed with tissue Doppler imaging (TDI)
from apical views to evaluate longitudinal myocardial
regional function, analyzing septal, inferior, lateral, ante-
rior and posterior walls. Velocity profiles were recorded
with a sample volume placed in the middle of the basal
segment of each LV wall. TDI signals were recorded at a
sweep of 100 mm/s. Intraventricular asynchronism was
defined as the time difference between the shortest and
longest electromechanical delay among the five LV walls
[14]. Responders were defined as a post-CRT decrease in
LV end-systolic volume ≥ 15% at the 3–6 months follow-
up echocardiography [14]. The wall motion score index
(WMSI) was quantified at rest and during DSE, using a 16-
segment model as recommended [13]. DSE was per-
formed according to a low-dose infusion protocol.
Patients received 5, 10, 15, and 20 μg/kg/min of dob-
utamine in 3-minutes stages, with echocardiographic
images recorded at the end of each stage. The presence of
LV contractile reserve (CR) was defined as an improve-
ment of ≥ 0.20 in WMSI (rest-DSE). Heart rate and blood
pressure were monitored during each stage. Criteria for
stopping dobutamine infusion were (1) hypotension
(systolic blood pressure < 90 mmHg), (2) angina, (3) sig-
nificant arrhythmias (atrial fibrillation, bigeminy, ven-
tricular tachycardia), (4) achievement of 85% maximal
predicted heart rate.
CRT implantation
A coronary sinus venogram was obtained using balloon
catheter, followed by the insertion of the LV pacing lead.
An SF guiding catheter was used to position the LV lead
(Guidant Corporation, St Paul, NM or Medtronic Inc,
Minneapolis, MN) in the coronary sinus.Cardiovascular Ultrasound 2009, 7:39 http://www.cardiovascularultrasound.com/content/7/1/39
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The preferred position was lateral or postero-lateral vein.
Right atrial and ventricular leads were positioned conven-
tionally. All leads were connected to a dual-chamber biv-
entricular ICD (Guidant Corporation, or Medtronic Inc).
Blood sampling and NT-pro BNP measurement
Venous blood samples were withdrawn from an antecu-
bital vein into chilled ethylene-diamine-tetra-acetic acid
Vacutainer test tubes after 20 minutes of rest with patients
in a supine position. Samples were placed immediately on
ice-cold water and the tubes were then centrifuged at 4000
r.p.m. at 4°C for 15 min. Supernatant plasma was then
immediately aliquoted into labelled cryo-vials. NT-pro
BNP was determined by a commercially available electro-
chemiluminescence immunoassay based on a polyclonal
antibody-based sandwich chemiluminescence assay
(Roche Diagnostics, Germany) using an autoanalyser
(Elecsys 2010).
Statistical analysis
Continuous variables are expressed as mean ± SD or mean
± SEM when specified. Patients were separated into 2
groups (responders and non-responders). Baseline data
for responders versus non-responders groups were com-
pared for statistical significance using t-test or chi-square
test, as appropriate. Baseline and post-CRT Doppler-
echocardiographic data were analyzed using a 2-way anal-
ysis of variance for repeated measurements to assess the
effects of time (baseline vs. post-CRT) and group (non-
responders vs. responders). Linear regression analyses
were used to evaluate the relationship between changes in
NT-pro BNP and changes in echocardiographic parame-
ters. Sensitivity and specificity for identification of CRT
responders were determined for various cut-off values of
echocardiographic parameters using receiver-operating
characteristic (ROC) curves.
Forward and backward multiple stepwise regression were
performed to determine the association between the
change in NT-pro BNP and LV end-systolic volume after
adjustment for baseline variables. Logistic regression was
also performed to assess the performance of change in NT-
pro BNP to identify CRT responders.
Results
Among the 42 patients included in this study (mean age
66 ± 12 years, male 68%), 29 (69%) were responders.
There was no significant difference between responders
and non-responders (Table 1) regarding to age, preva-
lence of male gender, coronary artery disease, functional
NYHA class III or IV and left or right bundle branch block
at baseline. Although non-responders had significantly
more frequent intraventricular conduction defect than
responders (p = 0.04), there was no significant difference
between the 2 groups regarding pre-CRT pacing and PR
duration (Table 1). No significant difference between
groups was found for baseline and post CRT medication
at last follow-up.
NT-pro BNP at baseline and follow-up
The decrease in NT-pro BNP following CRT was higher in
responders than in non-responders (p = 0.002) (Figure 1).
Baseline mean NT-pro BNP was 3328 ± 2474 pg.ml-1
(25% quartile = 1186 pg.ml-1, median = 2776 pg.ml-1,
75% quartile = 5098 pg.ml-1) and was not statistically dif-
ferent between responders and non-responders (Figure 1)
Table 1: Baseline demographic and clinical data.
Variables All patients (n = 42) Responders (n = 29, 69%) Non-Responders (n = 13, 31%) P Value
Demographic data
Age, years 66 ± 12 66 ± 11 66 ± 15 0.83
Male, n (%) 30 (68) 19 (65) 10 (77) 0.45
CAD, n (%) 30 (68) 18 (62) 11 (85) 0.13
Clinical data
QRS duration, ms 159 ± 28 162 ± 27 155 ± 30 0.51
LBBB, n (%) 27 (61) 19 (65) 6 (46) 0.24
RBBB, n (%) 2 (4.5) 2 (7) 0 (0) ...
IVCD, n (%) 8 (18) 3 (10) 5 (38) 0.04
PR, ms 180 ± 40 172 ± 32 195 ± 51 0.08
Pre-CRT pacing, n (%) 7 (16) 5 (17) 2 (15) 0.88
NYHA III/IV, n (%) 31 (70)/13 (30) 22 (76)/7 (24) 7 (54)/6 (46) 0.16
Medication
Diuretic, n (%) 41 (93) 27 (93) 12 (92) 0.93
β-Blockers, n (%) 41 (93) 26 (90) 13 (100) 0.13
ACEi, n (%) 31 (70) 20 (69) 10 (77) 0.59
AR Blockers, n (%) 13 (30) 9 (32) 3 (23) 0.55
Digoxin, n (%) 11 (25) 5 (17) 6 (46) 0.06
Spironolactone, n (%) 26 (59) 15 (52) 10 (77) 0.12
CAD indicates coronary arteries disease, LBBB, left bundle branch block, RBBB, right bundle branch block, IVCD, intraventricular conduction 
defect, ACEi, angiotensin converting enzyme inhibitors and AR, angiotensin receptors.Cardiovascular Ultrasound 2009, 7:39 http://www.cardiovascularultrasound.com/content/7/1/39
Page 4 of 10
(page number not for citation purposes)
(3346 ± 2401 pg.ml-1 and 3286 ± 695 pg.ml-1, p = 0.95).
The change in NT-pro BNP between pre-CRT and 3–6
months post CRT evaluations was significantly more
important in responders than in non-responders (abso-
lute: -1428 ± 1333pg.ml-1 vs.-61 ± 959 pg.ml-1, p = 0.002;
relative: -45 ± 28% vs. 2 ± 28%, p < 0.0001). Moreover,
there was a definite trend for significant difference
between the 2 groups with regards to 3–6 months NT-pro
BNP (p = 0.07).
Baseline and chronic changes in echocardiographic 
parameters
Baseline LV volumes, LVEF, resting LV WMSI, MR severity
(i.e. ERO, RV and prevalence of severe MR) and inter and
intraventricular asynchronism were not significantly dif-
ferent between responders and non-responders (Table 2).
However, non-responder patients had higher baseline LV
stroke volume than responders but after CRT this differ-
ence was no longer significant. As expected, LV geometry
and function as well as MR severity were significantly
improved in responders following CRT (Table 2). By def-
inition, patients with response to CRT had better improve-
ment of LV end-systolic volume compared to non-
responders (-42 ± 17 ml vs. 13 ± 24 ml, p < 0.0001 and -
26 ± 10% vs. -6 ± 10%, p < 0.0001).
Contractile Reserve
CR was present in 30 patients (71%) and responders had
significant higher prevalence of CR than non-responders
(83% vs. 46%, p = 0.02) (Table 2). Consistently, the
improvement in WMSI during DSE was more important
in responders than in non-responders (13.2 ± 7.8% vs. -
7.6 ± 9.2%, p = 0.048). Compared to patients without CR,
those with CR had significant lower baseline and follow-
up LV end-systolic volume (167 ± 56 vs. 213 ± 58 ml, p =
0.03 and 135 ± 52 vs. 207 ± 83 ml, p = 0.001, respec-
tively). They also had higher decrease in LV end-systolic
volume following CRT (-33 ± 5 vs. -6 ± 9 ml, p = 0.01).
According to the presence of CR, there was no significant
difference in baseline and post-CRT NT-pro BNP (p = 0.69
and p = 0.26). Although there was no significant differ-
ence in baseline ERO (17 ± 9 vs. 22 ± 11 mm2, p = 0.22),
patients with CR had lower ERO at follow-up (8 ± 7 vs. 20
± 14 mm2, p = 0.004) than those without CR.
Relations between changes in MR severity and 
echocardiographic parameters
Percent changes in ERO and in RV were correlated with
percent changes in LV end-systolic volume (ERO: r = 0.73,
p < 0.0001, RV: r = 0.53, p = 0.0008) (Figure 2) and end-
diastolic volumes (ERO: r = 0.62, p < 0.0001, RV: r = 0.49,
p = 0.002) (Figure 3).
However, only the change in ERO was correlated with the
peak WMSI and the change in WMSI during DSE (r = 0.39,
p = 0.018 and r = 0.42, p = 0.0098, respectively.
Relations between changes in NT-pro BNP and 
echocardiographic parameters
The percent change in NT-pro BNP correlated with per-
cent change in LVEF (r = 0.32, p = 0.038), LV stroke vol-
ume, (r = 0.31, p = 0.043), LV end-diastolic volume (r =
0.42, p = 0.006) and RV (r = 0.45, p = 0.003). The best cor-
relations were found with percent changes in LV end-
systolic volume (r = 0.60, p < 0.0001) and ERO (r = 0.59,
p = 0.0001) (Figure 4 and 5). Moreover there was also a
significant correlation between the percent change in
WMSI during dobutamine infusion and percent change in
NT-pro BNP (r = 0.50, p = 0.0007) (Figure 6). Patients
with CR had higher changes and percent change in NT-pro
BNP than those without CR (p = 0.0093 and p = 0.0047,
respectively).
Utilization of NT-pro BNP for identification of 
echocardiographic response to CRT and change in MR 
severity
After adjustment for age, change in NT-pro BNP remains
correlated with the percent change in LV end-systolic vol-
ume (r = 0.58, p = 0.0001). ROC curve analysis, demon-
strated that the absolute change in NT-pro BNP is accurate
to identify response to CRT (area under curve = 0.82) and
that a decrease in BNP ≥ 277 pg.ml-1 identifies echocardi-
ographic responders (Figure 7) with good sensitivity
(83%), specificity (77%), positive predictive value (89%)
and negative predictive value (64%). The percent change
in NT-pro BNP was slightly more accurate (area under
curve = 0.88) with a sensitivity of 90%, a specificity of
Changes in Nt-pro BNP in responders and non responders  defined as a decrease ≥ 15% in LV end systolic volume 3 to 6  months post CRT Figure 1
Changes in Nt-pro BNP in responders and non 
responders defined as a decrease ≥ 15% in LV end 
systolic volume 3 to 6 months post CRT. Data are 
expressed as mean ± SEM.Cardiovascular Ultrasound 2009, 7:39 http://www.cardiovascularultrasound.com/content/7/1/39
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77%, a positive predictive value of 90% and a negative
predictive value of 75%, for percent decrease NT-pro BNP
≥ 15% (Figure 8). In multivariate linear regression, after
adjustment for age, sex, baseline LVEF and LV end-systolic
volume, percent change in NT-pro BNP was independ-
ently associated with percent of change in LV end-systolic
volume (β = 0.43 ± 0.14, p = 0.004).
Multivariate logistic regression showed, after adjustment
for other baseline variables, that the percent change in NT-
pro BNP is a good surrogate marker of response to CRT
(odds-ratio = 1.08 (95% confidence interval: 1.03–1.16)
per 1% of decrease in NT-pro BNP, p = 0.008). Similar
results were found when adding CR in the multivariate
models. When entering, the change in NT-pro BNP as a
dichotomous variable in the multivariate logistic model,
an absolute decrease in NT-pro BNP ≥ 277 pg.ml-1 and a
percent decrease of ≥ 15% were independently associated
with a 9.4-fold (p = 0.0056) and 7.1-fold (p = 0.0018)
increase in the likelihood of positive response to CRT,
respectively. Multivariate linear regression also identified
the percent change in NT-pro BNP ≥ 15%, after adjusting
for baseline characteristics (i.e. age, sex, ERO and LV end-
systolic volume), as strongly associated with the percent
change in ERO (β = 37 ± 8.5, p < 0.0001).
Discussion
The main finding of our study is that change in NT-pro
BNP level between baseline and 3 to 6 months after CRT
may be useful to identify (1) echocardiographic respond-
ers following CRT and (2) the magnitude of decrease in
MR severity following CRT. Our results also confirm that
change in MR severity after CRT implantation is related to
the improvement in LV geometry. Furthermore, previous
studies found that baseline LV viability is a strong predic-
tor of LV performance following CRT [12-14]. Hence, cor-
relation between the change in LV WMSI during DSE and
the change in NT-pro BNP (Figure 4), emphasized by our
data, suggests that a substantial amount of recruitable
myocardium is needed to obtain improvement in LV
function and MR and thus decrease in NT-pro BNP after
CRT. Consistently, we also confirmed results from previ-
ous studies showing that the presence of CR is a good pre-
dictor [15-17] of response to CRT.
Table 2: Baseline and late post-CRT Echocardiographic data.
Variables All patients (n = 42) Responders (n = 29, 69%) Non Responders (n = 13, 31%) P Value
LV geometry and function
LV end-systolic Volume, ml
Baseline 177 ± 65 175 ± 64 189 ± 62 0.49
Late post-CRT 155 ± 67 133 ± 57* 198 ± 67 0.0017
LV end-diastolic Volume, ml
Baseline 213 ± 69 209 ± 67 228 ± 67 0.40
Late post-CRT 201 ± 73 181 ± 66* 239 ± 72* 0.01
LV stroke Volume, ml
Baseline 42 ± 13 39 ± 10 50 ± 13 0.0048
Late post-CRT 51 ± 11 51 ± 9* 49 ± 14 0.65
LV ejection fraction, %
Baseline 19 ± 7 18 ± 7 19 ± 7 0.75
Late post-CRT 24 ± 9 27 ± 9* 18 ± 6 0.0025
Wall Motion Score Index
Baseline rest 3.5 ± 0.4 3.4 ± 0.4 3.6 ± 0.2 0.29
Baseline dobutamine 3.1 ± 0.4 3 ± 0.4* 3.3 ± 0.4* 0.038
Contractile Reserve, n (%) 30 (71) 24 (83) 6 (46) 0.02
Mitral Regurgitation
Effective orifice Area, mm2
Baseline 18 ± 13 18 ± 12 17 ± 14 0.73
Late post-CRT 10 ± 11 5 ± 5* 19 ± 15 < 0.0001
Regurgitant Volume, ml
Baseline 29 ± 26 31 ± 29 25 ± 19 0.54
Late post-CRT 17 ± 17 11 ± 13* 29 ± 19 0.0009
Severe Mitral Regurgitation, n (%)
Baseline 19 (45) 12 (41) 7 (54) 0.45
Late post-CRT 10 (61) 2 (7)* 8 (61) 0.0005
Asynchronism
Interventricular, ms 46 ± 27 46 ± 30 45 ± 22 0.92
Intraventricular, ms 85 ± 25 85 ± 25 85 ± 27 0.93
LV indicates left-ventricular and CRT, cardiac resynchronisation therapy. * significant difference (p < 0.05) between baseline and late post-CRT or 
between rest and dobutamine data; severe mitral regurgitation is defined as an effective orifice area ≥ 20 mm2.Cardiovascular Ultrasound 2009, 7:39 http://www.cardiovascularultrasound.com/content/7/1/39
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Cardiac resynchronization therapy and brain natriuretic 
peptide
Several previous studies reported a significant decrease in
natriuretic peptide following CRT implantation [8,18-24].
Recently, Fruhwald et al. [11] demonstrated, in patients
with moderate or severe HF and LV dyssynchrony, that
CRT exerts an early and sustained reduction in NT-pro
BNP reflecting the improvements in LV geometry and
function. Moreover, the Care-HF post-hoc analysis con-
cluded that NT-pro BNP may be used to monitor CRT
effect. Consistently, Kubanek et al[18] found similar
results and reported that a decrease in BNP > 6.7%
between baseline and 3 months follow-up is accurate to
differentiate responders from non-responders patients
(specificity = 77% and sensibility = 90%). Importantly
and in accordance with other studies, our results suggest
that baseline neurohumoral activities do not predicts the
effect of CRT. Indeed, response to CRT [25] is clearly a
multifactor process including the severity of intraventricu-
lar asynchrony, presence and localisation of LV viability,
Correlation between changes in effective regurgitant orifice  (ERO) area and changes in LV end-systolic volumes Figure 2
Correlation between changes in effective regurgitant 
orifice (ERO) area and changes in LV end-systolic vol-
umes.
Correlation between changes in effective regurgitant orifice  (ERO) area and changes in LV end-diastolic volumes Figure 3
Correlation between changes in effective regurgitant 
orifice (ERO) area and changes in LV end-diastolic 
volumes.
Correlation between changes in NT-pro BNP and changes in  LV end-systolic volume Figure 4
Correlation between changes in NT-pro BNP and 
changes in LV end-systolic volume.
Correlation between changes in NT-pro BNP and changes in  effective regurgitant orifice (ERO) area Figure 5
Correlation between changes in NT-pro BNP and 
changes in effective regurgitant orifice (ERO) area.Cardiovascular Ultrasound 2009, 7:39 http://www.cardiovascularultrasound.com/content/7/1/39
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and lead placement with respect to the latest LV activation
site. In contrast, NT-pro BNP release is essentially deter-
mined by LV wall stress. Hence, it is not surprising that
baseline NT-pro BNP is not accurate to predict clinical or
echocardiographic response after CRT.
Mechanism of changes in NT-pro BNP following CRT
Mechanism underlying CRT benefit in patients with HF is
related to reduction of LV dyssynchrony and correspond-
ing stress-strain disparities and inefficient ventricle con-
traction. Ultimately, CRT significantly improves both LV
function and geometry. This effect results in a decrease in
mitral valve tethering and in a concomitant increase in
mitral closing forces which, in turn, lead to significant
improvement of MR severity. Furthermore, because elec-
trical conduction and regional wall thickening are influ-
enced by the extent of myocardial fibrosis, it has been
hypothesized that long-term response to CRT could corre-
late with myocardial viability in patients with LV dysfunc-
tion.
Using nuclear myocardial perfusion imaging (2C1Ti),
magnetic resonance imaging, and DSE, several studies
have demonstrated the importance of LV viability in pre-
dicting response to CRT [26-32]. In accordance with these
studies, our results suggest that LV remodeling and
decrease in natriuretic peptides post CRT seem to be, at
least in part, determined by the presence and extent of
myocardial viability. In summary, NT-pro BNP can rap-
idly drop when cardiac therapy provides significant
improvement in LV geometry and function. Obviously,
the impact of CRT on both LV and MR is the basic mech-
anism involved in the change in NT-pro BNP.
Contractile reserve and response to CRT
Several recent studies had underlined the crucial role of
myocardial CR to allow LV reverse remodeling[15,16,29]
and clinical improvement[17] following CRT. Moonen et
Correlation between changes in NT-pro BNP and changes in  LV wall motion score index (WMSI) during dobutamine  stress echocardiography Figure 6
Correlation between changes in NT-pro BNP and 
changes in LV wall motion score index (WMSI) dur-
ing dobutamine stress echocardiography.
Receiver-operating characteristic (ROC) curves analysing the  accuracy of absolute changes in NT-pro BNP to identify CRT  response Figure 7
Receiver-operating characteristic (ROC) curves ana-
lysing the accuracy of absolute changes in NT-pro 
BNP to identify CRT response.
Receiver-operating characteristic (ROC) curves analysing the  accuracy of relative changes in NT-pro BNP to identify CRT  response Figure 8
Receiver-operating characteristic (ROC) curves ana-
lysing the accuracy of relative changes in NT-pro 
BNP to identify CRT response.Cardiovascular Ultrasound 2009, 7:39 http://www.cardiovascularultrasound.com/content/7/1/39
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al. [15] showed that response to CRT mainly depends not
only on the extent of LV dyssynchrony and MR severity
but also on the presence of CR. In addition, CR may be
useful to predict CRT response, evaluated either with DSE
[33] or with exercise echocardiography[15,16]. Our
results confirm that CR is essential to reach satisfactory LV
reverse remodeling and response to CRT and that NT pro
BNP is an accurate surrogate marker of LV improvement
following CRT.
Clinical implications
BNP is widely considered as useful marker for the diagno-
sis and prognosis of HF and may be helpful to guide med-
ical management. The presence of high plasma BNP levels
is associated with an increased risk of cardiac events and
death in patients with chronic HF. The titration of HF
treatment based on the reduction of plasma NT-pro BNP
concentrations has been found to be superior to treatment
with empirical trial-based therapy dictated by clinical
judgment. NT-pro BNP is routinely used in patients with
HF and is an accurate marker of LV and clinical status.
Recently, Miller et al. [34] found in a prospective series of
172 ambulatory HF patients that a significant increase in
BNP was associated with markedly reduced event-free sur-
vival. However, only large decrease of BNP concentrations
led to outcome improvement. More modest increases or
decreases seem to confer little additional predictive value.
Furthermore, our results showed that NT-pro BNP is also
a good surrogate marker to identify LV remodeling and
MR reduction following CRT. More importantly, NT-pro
BNP monitoring allows the clinician to accurately identify
echocardiographic responders to CRT. Since LV remode-
ling predicts outcome with better accuracy than clinical
improvement after CRT [35] and that NT-pro BNP moni-
toring can identify echocardiographic responders with a
very good sensitivity and specificity, assessment of NT
pro-BNP after CRT could be used as an additional tool to
assist the clinician in the evaluation of the patient's condi-
tion (additional file 1 and 2). The main finding of this
study is that LV remodeling can be identified by change in
neurohormone level early (3–6 months) after CRT.
Patients identified as non responders may be followed
more closely. This subgroup of patients may have a differ-
ent clinical management: re-evaluation of coronary-sinus
lead position, programming of timing intervals, shorter
time periods between follow-up evaluations, cardiac
transplantation or other surgical options.
Limitation
The main limitation of this study is the relatively the small
number of patients, which reduced the statistical power
for multivariate analyses. In addition, the studied popula-
tion had various LV dysfunction etiologies, including
ischemic and non-ischemic myocardial dysfunction. Nev-
ertheless, this also underlines that NT-pro BNP is reliable
even in heterogeneous population of CRT patients. Dys-
synchrony was defined by longitudinal TDI using a cut-off
value of 50 ms on as inclusion criterion. Combining lon-
gitudinal and radial dyssynchrony index as inclusion cri-
terion could have been helpful in choosing a more
homogenous population prone to CRT response.
Conclusion
Results of this study show that NT-pro BNP monitoring
can accurately identify echocardiographic responders after
CRT. Decrease in NT-pro BNP ≥ 15% during follow-up is
a good surrogate marker of favourable LV remodeling and
MR reduction following CRT. Monitoring of NT-pro BNP
may be useful for the management of patients with HF
and CRT.
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